Your role of the antagonist is wearing thin, we have directed you to several previous Trials, MPL is a singular compound, PAA are varying delivery methods, the same singular compound MPL has over $100m worth of Human research from Eli Lilly ,,education is everything from previous History here.... re purposing is nothing New and covers much previous broken ground saving time and Money.. I'm very confident of my Investment here, PR and Marketing seem to be the companys Achillies Heel , unable to obtain traction with the SP,,,and ratchet value up.
Ann: Optimisation of Monepantel Uptake, page-6
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
0.015(6.98%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 23.0¢ | 21.5¢ | $475.3K | 2.128M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 93524 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 71004 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |
Day chart unavailable
